RESUMO
Detection of anomalous cells such as cancer cells from normal blood cells has the potential to contribute greatly to cancer diagnosis and therapy. Conventional methods for the detection of cancer cells are usually tedious and cumbersome. Herein, we report on the use of a particle size analyzer for the convenient size-based differentiation of cancer cells from normal cells. Measurements made using a particle size analyzer revealed that size parameters for cancer cells are significantly greater (e.g., inner diameter and width) than the corresponding values for normal cells (white blood cells (WBC), lymphocytes and splenocytes), with no significant difference in shape parameters (e.g., circularity and convexity). The inner diameter of many cancer cell lines is greater than 10 µm, in contrast to normal cells. For the detection of WBC having similar size to that of cancer cells, we developed a PC software "Cancer Cell Finder" that differentiates them from cancer cells based on brightness stationary points on a cell surface. Furthermore, the aforementioned method was validated for cancer cell/clusters detection in spiked mouse blood samples (a B16 melanoma mouse xenograft model) and circulating tumor cell cluster-like particles in the cat and dog (diagnosed with cancer) blood samples. These results provide insights into the possible applicability of the use of a particle size analyzer in conjunction with PC software for the convenient detection of cancer cells in experimental and clinical samples for theranostics.
Assuntos
Neoplasias da Mama/patologia , Neoplasias Colorretais/patologia , Neoplasias Pulmonares/patologia , Melanoma Experimental/patologia , Neoplasias da Próstata/patologia , Animais , Neoplasias da Mama/sangue , Neoplasias da Mama/diagnóstico , Gatos , Linhagem Celular Tumoral , Forma Celular , Tamanho Celular , Neoplasias Colorretais/sangue , Neoplasias Colorretais/diagnóstico , Cães , Feminino , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Humanos , Leucócitos/citologia , Leucócitos/patologia , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/diagnóstico , Linfócitos/citologia , Linfócitos/patologia , Masculino , Melanoma Experimental/sangue , Melanoma Experimental/diagnóstico , Camundongos Endogâmicos C57BL , Neoplasias da Próstata/sangue , Neoplasias da Próstata/diagnóstico , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Software , Baço/citologia , Baço/patologia , Propriedades de Superfície , Nanomedicina Teranóstica/instrumentação , Nanomedicina Teranóstica/métodosRESUMO
The presence of (1 â 3)-ß-D-glucan in human plasma is a marker for fungal infections. Currently, the Limulus amebocyte lysate (LAL)-based assay is widely used for the quantification of plasma (1 â 3)-ß-D-glucan. However, it has limitations in clinical use, such as an unstable supply of natural resources, complicated manufacturing process, and low-throughput of the reagents. Alternative assays exploiting specific antibodies against (1 â 3)-ß-D-glucan have been developed to overcome these challenges. However, these methods are associated with low sensitivity and poorly correlate with the data obtained by the LAL-based assay. The aim of this study is to develop a novel enzyme immunoassay that is as sensitive and accurate in determining plasma (1 â 3)-ß-D-glucan levels as compared to that obtained with the LAL-based assay. We generated specific monoclonal antibodies against (1 â 3)-ß-D-glucan that recognizes four-unit glucose oligomers with (1 â 3)-ß-D-linkages, and constructed a sandwich enzyme-linked immunosorbent assay (ELISA) using these antibodies. The newly developed ELISA showed proportional increase in absorbance with the volume of (1 â 3)-ß-D-glucan added. The limit of detection of the assay was 4 pg/ml of plasma (1 â 3)-ß-D-glucan that was equivalent to the LAL-based assay and the working range was 4-500 pg/ml. The intra-assay coefficient of variation was 2.2-5.4% using three different concentrations of plasma samples. We observed strong correlation (R = 0.941, slope = 0.986) between the measurements obtained by our ELISA and Fungitec G test ES Nissui, a commonly used LAL-based assay, using 26 types of plasma samples. This could be attributed to the epitopes of the antibodies. Both antibodies could inhibit the LAL-based assay, suggesting that the antibodies recognize the identical regions in ß-D-glucan, thereby inactivating factor G, an initiation zymogen for coagulation cascade, in the LAL-based assay. Thus, the ELISA developed in this study can detect fungal infections in clinical settings with similar efficiency as the LAL-based assay. This assay is characterized by good performance, stable supply of materials, and simple manufacturing process and is more suitable for the high-throughput diagnosis of fungal infections.
Assuntos
Anticorpos Monoclonais/imunologia , Ensaio de Imunoadsorção Enzimática , Teste do Limulus , Micoses/diagnóstico , beta-Glucanas/sangue , Afinidade de Anticorpos , Especificidade de Anticorpos , Biomarcadores/sangue , Epitopos , Humanos , Micoses/sangue , Micoses/imunologia , Micoses/microbiologia , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , beta-Glucanas/imunologiaRESUMO
c-Met is a receptor-type tyrosine kinase, which is involved in a wide range of cellular responses such as proliferation, motility, migration and invasion. It has been reported to be overexpressed in various cancers. However, the role of c-Met in breast cancer stem cells (CSCs) still remains unclear. We herein, show that c-Met expression is significantly elevated in Basal-like type of breast cancer in comparison with other subtypes. High expression of c-Met strongly correlated with the expression of two CSC markers, ALDH1A3 and CD133 in breast cancers. In addition, breast cancers at tumor stage III-IV expressing both c-Methigh and ALDH1A3high had poor prognosis. Furthermore, treatment with c-Met inhibitors (Crizotinib, Foretinib, PHA-665752 and Tivantinib) in MDA-MB157 cells with high c-Met protein expression resulted in significant suppression in cell viability, contrary to MDA-MB468 cells with low c-Met protein expression. These c-Met inhibitors also suppressed cell viability and tumor-sphere formation of ALDH1high breast cancer cells with high c-Met expression. These results suggest that c-Met in ALDH1 positive CSCs seems to play an important role in breast cancer repopulation. Therefore, we conclude that c-Met is a potential therapeutic target in ALDH1 positive breast CSCs.